![Jeff Hargroves](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeff Hargroves
Directeur/Membre du Conseil chez
CINGULATE INC.
Fortune : 405 467 $ au 31/05/2026
Profil
Mr. Jeff Hargroves is an Independent Director at Cingulate, Inc., an Advisor at Riverside Partners LLC, an Independent Director at Cingulate Works, Inc., a Manager at Hargroves Family Investments LLC and a Treasurer & Director at The Greater Kansas City Community Foundation.
He is on the Board of Directors at Cingulate, Inc., Elixell Therapeutics, Inc., Cingulate Therapeutics LLC, Cingulate Works, Inc., Kansas City Symphony and The Greater Kansas City Community Foundation.
Mr. Hargroves was previously employed as a Board member by Orbis Biosciences, Inc., a President, Secretary & Director by KCBN Holding, Inc., a Founder & president by ProPharma Group LLC, and a Director-Production by Ivy Animal Health, Inc. He also served on the board at ALZA Corp.
He received his undergraduate degree from the University of Missouri.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CINGULATE, INC. 0,73% | 18/05/2026 | 97 468 ( 0,73% ) | 405 467 $ | 31/05/2026 |
Postes actifs de Jeff Hargroves
| Sociétés | Poste | Début |
|---|---|---|
| CINGULATE INC. | Directeur/Membre du Conseil | 13/02/2026 |
Cingulate Therapeutics LLC
 Cingulate Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on develops attention deficit/hyperactivity disorder products | Directeur/Membre du Conseil | 01/01/2019 |
The Greater Kansas City Community Foundation
 The Greater Kansas City Community Foundation Investment Trusts/Mutual FundsMiscellaneous Provides services for the downtrodden and homeless people | Directeur/Membre du Conseil | - |
Cingulate Works, Inc.
 Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for the treatment of central nervous system and neurobiological disorders | Directeur/Membre du Conseil | 01/06/2018 |
Hargroves Family Investments LLC | Corporate Officer/Principal | - |
Elixell Therapeutics, Inc. | Directeur/Membre du Conseil | 01/01/2019 |
Riverside Partners LLC
 Riverside Partners LLC Investment ManagersFinance Riverside Partners invests in middle-market companies located in the United States primarily in North America with an EBITDA of USD 3 - 15 million. The firm focuses on technology and healthcare sectors. It participates in buyouts, recapitalizations, growth equity, divestitures, take private transactions and strategic add-on acquisitions. It makes control investments. | Consultant / Advisor | 01/01/2021 |
Kansas City Symphony
 Kansas City Symphony Movies/EntertainmentConsumer Services Operates as symphony | Directeur/Membre du Conseil | - |
Anciens postes connus de Jeff Hargroves
| Sociétés | Poste | Fin |
|---|---|---|
| CINGULATE INC. | Directeur/Membre du Conseil | 23/09/2022 |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jeff Hargroves
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
88
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology Provides and develops pharmaceutical products | Health Technology |
Adare Pharmaceuticals Usa, Inc.
 Adare Pharmaceuticals Usa, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of materials science and pharmaceutics | Commercial Services |
Cingulate Therapeutics LLC
Cingulate Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on develops attention deficit/hyperactivity disorder products | Health Technology |
University of Missouri
 University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Riverside Partners LLC
Riverside Partners LLC Investment ManagersFinance Riverside Partners invests in middle-market companies located in the United States primarily in North America with an EBITDA of USD 3 - 15 million. The firm focuses on technology and healthcare sectors. It participates in buyouts, recapitalizations, growth equity, divestitures, take private transactions and strategic add-on acquisitions. It makes control investments. | Finance |
The Greater Kansas City Community Foundation
The Greater Kansas City Community Foundation Investment Trusts/Mutual FundsMiscellaneous Provides services for the downtrodden and homeless people | Miscellaneous |
Ivy Animal Health, Inc.
 Ivy Animal Health, Inc. Pharmaceuticals: MajorHealth Technology Provides applied research and pharmaceutical product development services | Health Technology |
Kansas City Symphony
Kansas City Symphony Movies/EntertainmentConsumer Services Operates as symphony | Consumer Services |
KCBN Holding, Inc.
 KCBN Holding, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
ProPharma Group LLC
 ProPharma Group LLC Miscellaneous Commercial ServicesCommercial Services Provides clinical, quality, compliance, medical information and pharmacovigilance services for the life sciences industry | Commercial Services |
Cingulate Works, Inc.
Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for the treatment of central nervous system and neurobiological disorders | Health Technology |
Cingulate, Inc.
 Cingulate, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Hargroves Family Investments LLC | |
Elixell Therapeutics, Inc. |
